242 related articles for article (PubMed ID: 26945581)
1. Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study.
Chakraborty S; Filippi CG; Wong T; Ray A; Fralin S; Tsiouris AJ; Praminick B; Demopoulos A; McCrea HJ; Bodhinayake I; Ortiz R; Langer DJ; Boockvar JA
J Neurooncol; 2016 Jul; 128(3):405-15. PubMed ID: 26945581
[TBL] [Abstract][Full Text] [Related]
2. Superselective intraarterial cerebral infusion of cetuximab with blood brain barrier disruption combined with Stupp Protocol for newly diagnosed glioblastoma.
Kulason KO; Schneider JR; Chakraborty S; Filippi CG; Pramanik B; Wong T; Fralin S; Tan K; Ray A; Alter RA; Ortiz R; Demopoulos A; Langer DJ; Boockvar JA
J Exp Ther Oncol; 2018 May; 12(3):223-229. PubMed ID: 29790314
[TBL] [Abstract][Full Text] [Related]
3. Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial.
McCrea HJ; Ivanidze J; O'Connor A; Hersh EH; Boockvar JA; Gobin YP; Knopman J; Greenfield JP
J Neurosurg Pediatr; 2021 Aug; 28(4):371-379. PubMed ID: 34359048
[TBL] [Abstract][Full Text] [Related]
4. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article.
Boockvar JA; Tsiouris AJ; Hofstetter CP; Kovanlikaya I; Fralin S; Kesavabhotla K; Seedial SM; Pannullo SC; Schwartz TH; Stieg P; Zimmerman RD; Knopman J; Scheff RJ; Christos P; Vallabhajosula S; Riina HA
J Neurosurg; 2011 Mar; 114(3):624-32. PubMed ID: 20964595
[TBL] [Abstract][Full Text] [Related]
5. Durability of single dose intra-arterial bevacizumab after blood/brain barrier disruption for recurrent glioblastoma.
Chakraborty S; Filippi CG; Burkhardt JK; Fralin S; Ray A; Wong T; Ortiz R; Langer DJ; Boockvar JA
J Exp Ther Oncol; 2016 Nov; 11(4):261-267. PubMed ID: 27849336
[TBL] [Abstract][Full Text] [Related]
6. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans.
Siegal T; Rubinstein R; Bokstein F; Schwartz A; Lossos A; Shalom E; Chisin R; Gomori JM
J Neurosurg; 2000 Apr; 92(4):599-605. PubMed ID: 10761648
[TBL] [Abstract][Full Text] [Related]
7. Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series.
Shin BJ; Burkhardt JK; Riina HA; Boockvar JA
Neurosurg Clin N Am; 2012 Apr; 23(2):323-9, ix-x. PubMed ID: 22440875
[TBL] [Abstract][Full Text] [Related]
8. [Intra-arterial chemotherapy of malignant glioma after osmotic blood-brain barrier disruption].
Yamada K; Takahama H; Nakai O; Takanashi T; Hosoya T
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2692-6. PubMed ID: 2506817
[TBL] [Abstract][Full Text] [Related]
9. Rechallenging Recurrent Glioblastoma with Intra-Arterial Bevacizumab with Blood Brain-Barrier Disruption Results in Radiographic Response.
Faltings L; Kulason KO; Patel NV; Wong T; Fralin S; Li M; Schneider JR; Filippi CG; Langer DJ; Ortiz R; Boockvar JA
World Neurosurg; 2019 Nov; 131():234-241. PubMed ID: 31351210
[TBL] [Abstract][Full Text] [Related]
10. [Intra-arterial infusion of high dose methotrexate therapy in recurrent gliomas].
Hayashi A; Kyuma Y
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1461-6. PubMed ID: 2117886
[TBL] [Abstract][Full Text] [Related]
11. [A case of recurrent malignant glioma treated by superselective intraarterial chemotherapy with a combination of etoposide and cisplatin].
Nakagawa H; Kubo S; Fujita T; Tsuruzono K; Miyawaki Y; Arita N; Hayakawa T
Gan To Kagaku Ryoho; 1992 Feb; 19(2):237-40. PubMed ID: 1736836
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic efficacy of intracarotid infusion of 20% mannitol with ACNU in Fischer rats with intracerebrally implanted 9L gliosarcoma].
Miyagami M; Tazoe M; Kasahara E; Tsubokawa T
Gan To Kagaku Ryoho; 1989 May; 16(5):2059-65. PubMed ID: 2499268
[TBL] [Abstract][Full Text] [Related]
13. Convection-enhanced delivery of cetuximab conjugated iron-oxide nanoparticles for treatment of spontaneous canine intracranial gliomas.
Freeman AC; Platt SR; Holmes S; Kent M; Robinson K; Howerth E; Eagleson J; Bouras A; Kaluzova M; Hadjipanayis CG
J Neurooncol; 2018 May; 137(3):653-663. PubMed ID: 29350351
[TBL] [Abstract][Full Text] [Related]
14. Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma.
Riina HA; Fraser JF; Fralin S; Knopman J; Scheff RJ; Boockvar JA
J Exp Ther Oncol; 2009; 8(2):145-50. PubMed ID: 20192120
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of GRN1005 in recurrent malignant glioma.
Drappatz J; Brenner A; Wong ET; Eichler A; Schiff D; Groves MD; Mikkelsen T; Rosenfeld S; Sarantopoulos J; Meyers CA; Fielding RM; Elian K; Wang X; Lawrence B; Shing M; Kelsey S; Castaigne JP; Wen PY
Clin Cancer Res; 2013 Mar; 19(6):1567-76. PubMed ID: 23349317
[TBL] [Abstract][Full Text] [Related]
16. [Reversible opening of the blood-brain barrier in the chemotherapy of malignant gliomas].
Heimberger K; Samec P; Podreka I; Binder H; Suess E; Reisner T; Deecke L; Steger G; Hiesmayr M; Dittrich C
Wien Klin Wochenschr; 1987 May; 99(11):385-8. PubMed ID: 3113082
[TBL] [Abstract][Full Text] [Related]
17. Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: where are we now, and where we are going.
D'Amico RS; Khatri D; Reichman N; Patel NV; Wong T; Fralin SR; Li M; Ellis JA; Ortiz R; Langer DJ; Boockvar JA
J Neurooncol; 2020 Apr; 147(2):261-278. PubMed ID: 32076934
[TBL] [Abstract][Full Text] [Related]
18. [ACNU delivery to malignant glioma tissue by osmotic blood brain barrier modification with intracarotid infusion of hyperosmoral mannitol].
Miyagami M; Kagawa Y; Tsubokawa T
No Shinkei Geka; 1985 Sep; 13(9):955-63. PubMed ID: 2999632
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma.
Neuwelt EA; Howieson J; Frenkel EP; Specht HD; Weigel R; Buchan CG; Hill SA
Neurosurgery; 1986 Oct; 19(4):573-82. PubMed ID: 3097567
[TBL] [Abstract][Full Text] [Related]
20. Osmotic blood-brain barrier disruption: pharmacodynamic studies in dogs and a clinical phase I trial in patients with malignant brain tumors.
Neuwelt EA; Hill SA; Frenkel EP; Diehl JT; Maravilla KR; Vu LH; Clark WK; Rapoport SI; Barnett PA; Lewis SE; Ehle AL; Beyer CW
Cancer Treat Rep; 1981; 65 Suppl 2():39-43. PubMed ID: 6809316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
